Quality
Return on invested capital, after tax
10.5% Computed
From the FY2025 filing
ValueScreener company report
Royalty Pharma plc (RPRX)
NASDAQ / Healthcare / Biotechnology
Share price
59.62 USD Market dataClose of Oct 15, 2026Market capitalisation
26.55B USD Market dataClose of Oct 15, 2026- Market data
- Oct 15, 2026
- Filed accounts
- FY2025, filed Feb 11, 2026
- Ratios computed
- Oct 15, 2026
- Filed years
- 8, FY2018 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
- SEC filingFiled with the SEC
- Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
- Company statementCompany statement
- What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
- Market dataMarket data
- Prices, market value and what analysts publish, with the date they are as of.
- ComputedComputed by ValueScreener
- Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading
1 of 10
Overview
What the business is, what it costs, and how it reads on four questions.
Market dataSEC filingComputed
Four questions, at a glance
Financial strength
Debt to equity
1.38 Computed
From the FY2025 filing
Valuation
Price to earnings
33.31x Computed
FY2025 accounts, priced at the latest close
Cash generation
Free cash flow yield
n/a Computed
FY2025 accounts, priced at the latest close
Why n/a
We do not hold this figure for this company, so there is nothing to show.
Revenue and net income, by fiscal year
- Named tests met
- 1 of 30 Which tests
The business, and the score behind its five axes
The reading, in brief
- Is it cheap
Price to earnings is 33.31x at the close of 2026-10-15 on FY2025 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits between 25.00x and 40.00x.
Today, against the Biotechnology industry (53 companies), 33.31x sits at the 73rd percentile; the middle half of that group runs from 4.71x to 41.19x.
- Is it good
Return on invested capital was 10.5% in FY2025, in the band labelled "Around the cost of capital" (8.0% to 12.0%), on lines anchored on Damodaran's cost-of-capital data.
Today, against the Biotechnology industry (78 companies), 10.5% sits at the 84th percentile; the middle half of that group runs from -124.0% to -4.0%.
- Is it safe
Interest coverage was 5.07x in FY2025, in the band labelled "Investment grade" (3.00x to 6.00x), on lines anchored on Damodaran's interest-coverage table.
- Year by year against peers
- Whether Royalty Pharma plc's return on equity stayed above the median of the Biotechnology industry, year by year. (FY2019 to FY2025, 7 fiscal years of Royalty Pharma plc with a comparable figure)
- The direction
- Which way Royalty Pharma plc's operating margin has moved, and how steadily. (FY2016 to FY2025, 10 filed years of Royalty Pharma plc)
- What could explain it
- What in Royalty Pharma plc's filed statements could explain the movements. (8 readings drawn from the statement lines Royalty Pharma plc filed)
- What to check next
- What to check next on Royalty Pharma plc, and where in its filings. (3 questions for Royalty Pharma plc)
- In one paragraph
- One paragraph on Royalty Pharma plc's returns, cash, balance sheet and price. (11 of sixteen figures read for Royalty Pharma plc)
These are RPRX’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.
Research RPRXPart of Serious. New accounts start with 30 days of Professional, free, no card.
2 of 10
What changed
The newest filing, what it moved, and when the next one is due.
SEC filingCompany statement
The newest accounts on file are the FY2025 annual report: 10-K, filed Feb 11, 2026, accession 0001802768-26-000003.
3 of 10
Quality
The returns the business earns on its capital, and the margins behind them.
SEC filingComputed
| Figure | Value, source and document |
|---|---|
| Return on invested capital, after tax | 10.5% ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Return on equity | 11.9% ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Return on capital employed, pre-tax | 8.2% ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Return on assets | 3.9% ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
Gross marginWhy n/aOur archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which. | n/a ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Operating margin | 65.6% ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Net margin | 32.4% ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
RPRX 32.4%
8.4%33.7%
4 of 10
Financial strength
What it owes against what it owns, and whether it can meet what falls due.
SEC filingComputedCompany statement
| Figure | Value, source and document |
|---|---|
| Debt to equity | 1.38 ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Current ratio | 2.40 ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Quick ratio | 2.40 ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Interest coverage | 5.07x ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Altman Z-score | 2.64 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Net debt | 8.33B ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
The balance sheet, line by line
Financial health
What Royalty Pharma plc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Feb 11, 2026, 0001802768-26-000003).
| Total assets | 19.62B FiledFY2025 10-K, filed Feb 11, 2026 |
|---|---|
| Total liabilities | 9.91B FiledFY2025 10-K, filed Feb 11, 2026 |
| Shareholders' equity | 6.48B FiledFY2025 10-K, filed Feb 11, 2026 |
| Cash | 637.5M FiledFY2025 10-K, filed Feb 11, 2026 |
| Total debt | 8.97B FiledFY2025 10-K, filed Feb 11, 2026 |
| Net debt | 8.33B |
| Current ratio | 2.40 |
| Debt to equity | 1.38 |
Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.
5 of 10
Valuation context
What the market charges for it, against its own record and companies like it.
Market dataSEC filingComputed
| Figure | Value, source and document |
|---|---|
| Price to earnings | 33.31x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| P/E on trailing twelve months | 30.90x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings |
| Price to book | 5.20x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Price to sales | 14.15x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Enterprise value to EBIT | 26.93x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Enterprise value to EBITDA | 26.87x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Price to earnings over growth | 5.30 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Diluted earnings per share | 1.78 USD FiledFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Graham number | 21.50 USD ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
We publish no fair value or price target of our own. Value RPRX on your own assumptions in the DCF workbench, starting from the filed figures.
Its own record, and companies like it
Valuation
What the market charges for Royalty Pharma plc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.
| Share price | 59.62 USD |
|---|---|
| Market capitalisation | 26.55B USD |
| Enterprise value to EBITDA | 26.87x |
| Graham number | 21.50 USD |
| Diluted earnings per share, FY2025 | 1.78 USD |
Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Aug 11, 2021: low 9.48x, median 25.61x, high 378.40x, latest 30.90x. 1,298 trading days with a meaningful ratio. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.
Companies like Royalty Pharma plc
- Genmab A/S (GMAB)Market cap 23.26B USD
- Vertex Pharmaceuticals Incorporated (VRTX)Market cap 128.90B USD
- Incyte Corporation (INCY)Market cap 22.96B USD
- Alnylam Pharmaceuticals, Inc. (ALNY)Market cap 31.32B USD
- Exelixis, Inc. (EXEL)Market cap 15.79B USD
Same industry (Biotechnology) and size band (Large, 10B to 200B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.
6 of 10
Cash generation
Whether profit arrives as cash, and what is paid back to shareholders.
Computed
| Figure | Value, source and document |
|---|---|
Free cash flow yieldWhy n/aWe do not hold this figure for this company, so there is nothing to show. | n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
Free cash flowWhy n/aThe FY2025 filing carries no free cash flow we could read. | n/a ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
Free cash flow marginWhy n/aNo free cash flow, and no operating cash flow and capital expenditure pair, is filed for this year. | n/a ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
Dividend yieldWhy n/aThe dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated. | n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
Payout ratioWhy n/aWe do not hold this figure for this company, so there is nothing to show. | n/a ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
7 of 10
Filings
Every figure, the year it is for and the document it was read from.
SEC filingMarket data
The filed figures
Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.
| Figure | Value | Year | As of |
|---|---|---|---|
| 33.31x | FY2025 | Oct 15, 2026 | |
FormulaShare price / earnings per share. Where the filing states no earnings per share this listing can be priced on, which is every 20-F and 40-F filer because theirs is stated per ordinary share, it is market capitalisation / net income: the same multiple, undiluted. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 5.20x | FY2025 | Oct 15, 2026 | |
FormulaMarket capitalisation / shareholders equity As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 26.93x | FY2025 | Oct 15, 2026 | |
Formula(Market capitalisation + total debt - cash) / operating income, or over the filing's own EBIT (income before tax + interest expense) where the filer tags no operating line, as Johnson & Johnson does not in any of its ten filed years. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| n/a | FY2025 | Oct 15, 2026 | |
| n/a The filed cash flow statement reports neither free cash flow nor the operating cash flow and capital spending it is built from. | |||
FormulaFree cash flow per share / share price x 100 As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 10.5% | FY2025 | Feb 11, 2026 | |
FormulaVendor trailing-twelve-month return on invested capital where one is published, which uses after-tax operating profit over total assets less current liabilities. Otherwise our own recompute: NOPAT / (shareholders equity + total debt - cash) x 100, where NOPAT is the filed operating profit after tax, or the filing's own EBIT after tax where the filer tags no operating line. As ofThe filing date of the statements below, for FY2025. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| n/a | FY2025 | Oct 15, 2026 | |
| n/a The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated. | |||
FormulaCommon dividends paid in the latest filed year / market capitalisation x 100. n/a where the filing cannot support it: a special or first-year payment, a total that mixes preferred dividends, or a cash-flow statement over 15 months old. As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 1.38 | FY2025 | Feb 11, 2026 | |
FormulaTotal debt / shareholders equity As ofThe filing date of the statements below, for FY2025. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 2.40 | FY2025 | Feb 11, 2026 | |
FormulaCurrent assets / current liabilities As ofThe filing date of the statements below, for FY2025. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 14.15x | FY2025 | Oct 15, 2026 | |
FormulaMarket capitalisation / revenue As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 5.30 | FY2025 | Oct 15, 2026 | |
FormulaPrice to earnings / the annual earnings growth rate, in percentage points As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 2.64 | FY2025 | Oct 15, 2026 | |
Formula1.2 x working capital/assets + 1.4 x retained earnings/assets + 3.3 x EBIT/assets + 0.6 x market value of equity/total liabilities + 1.0 x revenue/assets As ofThe close on Oct 15, 2026, over the filed figures of FY2025: a price is in this figure, and it moved after the filing. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| -2.64 | FY2025 | Feb 11, 2026 | |
FormulaAn eight-variable index of year-on-year changes in receivables, gross margin, asset quality, revenue, depreciation, overheads, leverage and accruals As ofThe filing date of the statements below, for FY2025. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
| 5/9 | FY2025 | Feb 11, 2026 | |
FormulaOne point each for: positive return on assets, positive operating cash flow, rising return on assets, operating cash flow above net income, falling leverage, rising current ratio, no new shares issued, rising gross margin, rising asset turnover. As ofThe filing date of the statements below, for FY2025. Form10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itIncome statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itBalance sheetFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tabForm10-KFiledFeb 11, 2026PeriodFY2025Accession0001802768-26-000003What we read from itCash flow statementFY2025Open on SEC.gov, accession 0001802768-26-000003, leaves this page and opens in a new tab | |||
The figures are computed from the accounts for fiscal 2025, the newest full year on file. 8 filed fiscal years on record, FY2018 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.
The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.
Ten years of filed figures, year by year
Ten years of filed figures
10 fiscal years, FY2016 to FY2025. 8 read from the annual reports Royalty Pharma plc filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in USD, as reported.
| Year | Revenue | Operating income | Net income | EPS, diluted | Free cash flow | Operating margin | Return on equity | Filing |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 2.38B | 1.56B | 770.9M | 1.78 | n/a | 65.6% | 11.9% | 10-K, Feb 11, 20260001802768-26-000003 |
| FY2024 | 2.26B | 1.29B | 859.0M | 1.91 | n/a | 57.1% | 12.4% | 10-K, Feb 12, 20250001802768-25-000010 |
| FY2023 | 2.35B | 1.49B | 1.13B | 2.53 | n/a | 63.4% | 17.4% | 10-K, Feb 15, 20240001802768-24-000012 |
| FY2022 | 2.24B | 307.1M | 42.8M | 0.10 | n/a | 13.7% | 0.8% | 10-K, Feb 15, 20230001802768-23-000007 |
| FY2021 | 2.29B | 1.43B | 619.7M | 1.49 | n/a | 62.5% | 10.7% | 10-K, Feb 15, 20220001802768-22-000011 |
| FY2020 | 2.12B | 1.60B | 975.0M | 1.32 | n/a | 75.2% | 20.2% | 10-K, Feb 24, 20210001802768-21-000006 |
| FY2019 | 1.81B | 2.62B | 2.35B | n/a | n/a | 144.6% | 38.5% | 10-K, Feb 24, 20210001802768-21-000006 |
| FY2018 | 1.79B | 1.36B | 1.38B | n/a | n/a | 76.0% | n/a | 10-K, Feb 24, 20210001802768-21-000006 |
| FY2017 | 1.60B | 939.7M | 1.21B | 3.42 | 1.42B | 58.8% | 27.1% | Market data, supplied Oct 15, 2026accession n/a |
| FY2016 | 1.88B | 722.9M | 565.9M | 0.93 | n/a | 38.5% | 12.7% | Market data, supplied Oct 15, 2026accession n/a |
- Revenue, compound annual growth FY2016 to FY2025: 2.7%
- Earnings, compound annual growth FY2016 to FY2025: 3.5%
- Earnings per share, compound annual growth FY2016 to FY2025: 7.5%
- Free cash flow: Fewer than two filed years carry free cash flow.
Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.
8 of 10
Risks and guardrails
The accounting screens, the published tests, and the lines you can set to be told.
ComputedCompany statement
| Figure | Value, source and document |
|---|---|
| Beneish M-score | -2.64 ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Piotroski F-score | 5/9 ComputedFY2025 10-K, filed Feb 11, 2026, 0001802768-26-000003 |
| Named tests met | 1 of 30 Computed |
| Beta | 0.18 ComputedClose of Oct 15, 2026 |
The named tests
Of 30 tests value investors published: 1 met, 26 not met, 3 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.
Which tests, by name(all 30)
- Meets
- ROIC at or above WACC
- Does not
- Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff)
- Not measured
- Dividends and buybacks; Cash-covered dividend; Cash-flow yield and ROIC. A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(8)
- Positive Earnings Streak: We hold 6 profitable filed years in a row; the test needs 10.
- Gross Margin: Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.
- Dividend Yield: The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.
- Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
- Free Cash Flow Yield: We do not hold this figure for this company, so there is nothing to show.
- Capex To Ocf: We do not hold this figure for this company, so there is nothing to show.
- Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
- Dividend Streak: The dividends on file cannot be split between common and preferred holders, so the common dividend cannot be stated.
9 of 10
Declared positions
Whether anybody here owns this company.
Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.
10 of 10
Next step
What to do with what you have read.
A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.
What this cannot tell you
- 8 figures could not be read on this company, among them Positive Earnings Streak, Gross Margin, Dividend Yield. Each blank in the table above names the rest, with its reason. 3 named tests come back incomplete because of them, which is neither met nor missed.
- We hold 8 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.
And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.
Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.
No card. 30 free days, and nothing is charged unless you choose a plan.
ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.
A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.